Pharmacotherapy, acupoint stimulation, and psychotherapy for perimenopausal women with anxiety, depression, and panic disorder: a systematic review and network meta-analysis of randomized controlled trials.

TL;DR

A network meta-analysis of 131 trials found that combining medication with psychotherapy ranked highest for depression and sleep quality in perimenopausal women, though no single approach dominated across all measured outcomes.

What the study found

Perimenopausal women face a narrow therapeutic window. Declining ovarian function triggers cascading hormonal shifts that frequently manifest as anxiety, depression, and panic disorders. This network meta-analysis pooled data from 131 randomized controlled trials involving 11,457 perimenopausal women to directly compare three treatment classes: pharmacotherapy, acupoint stimulation, and psychotherapy, either alone or in combination.

The analysis revealed a clear pattern: combined treatments outperformed single interventions across most clinical measures. The drug-plus-psychotherapy combination achieved the highest ranking probability (SUCRA = 92.4%) for reducing depressive symptoms on the Hamilton Depression Rating Scale. For sleep quality, this same combination ranked even higher (SUCRA = 98.1% on the Pittsburgh Sleep Quality Index). When measuring menopausal symptoms via the Kupperman Index, drug-plus-psychotherapy again ranked first (SUCRA = 97.9%). The findings suggest additive or synergistic effects when pharmaceutical and psychological approaches are layered together.

Notably, the results were not uniform across all outcome measures. For anxiety specifically measured by the Hamilton Anxiety Rating Scale, the acupoint-stimulation-plus-psychotherapy combination ranked highest (SUCRA = 93.7%). Psychotherapy alone performed best for self-rated anxiety (SUCRA = 98.9% on the Self-rating Anxiety Scale), suggesting that subjective anxiety perception may respond differently to pure psychological intervention than clinician-assessed anxiety. The drug-plus-acupoint-stimulation combination ranked lowest for clinical efficacy overall but highest for luteinizing hormone reduction, indicating mechanistic specificity: different combinations may target different physiological pathways.

In pharmacological subgroup analyses, the data stratified treatments by drug class. Antidepressants combined with Traditional Chinese medicine ranked highest for depression outcomes and safety tolerability (SUCRA = 82% for adverse events). Antidepressants plus antipsychotics showed the best anxiety reduction (SUCRA = 97.5%). Antidepressants plus hormone replacement therapy ranked poorly for clinical efficacy (SUCRA = 10.2%), a noteworthy finding given the biological rationale for combining psychiatric and hormonal interventions. The control group (no active treatment) ranked highest for safety (SUCRA = 65.5%), an expected result but one that reflects only the absence of intervention-related adverse events, not the absence of suffering from untreated symptoms.

What this means for you

This analysis supports an individualized, layered approach to perimenopausal mood and anxiety symptoms. If you experience depression during this phase, evidence now suggests pairing an antidepressant with psychotherapy offers stronger outcomes than either approach alone. If anxiety is your primary concern, psychotherapy alone or combined with acupoint stimulation may be equally effective, giving you options aligned with your preferences.

The finding that different combinations excel at different outcomes matters practically. If sleep disruption is driving your symptoms, the drug-plus-psychotherapy pairing showed the strongest effect. If you're prioritizing safety and tolerability, antidepressants with Traditional Chinese medicine approaches ranked highly. This suggests working with your provider to clarify your treatment priority (depression vs. anxiety vs. sleep vs. menopausal symptoms broadly) and then matching the combination accordingly.

One caveat: this analysis pooled trials globally, including many from China and other regions where acupoint stimulation and Traditional Chinese medicine are standard care. Trial quality and outcome measurement methodology likely varied. The evidence tier here is B because network meta-analyses are more vulnerable to heterogeneity bias than large prospective trials, and the underlying RCTs may have had variable rigor.

Behavioral interventions like [psychotherapy] appear in these data as a core component of top-ranking combinations. This aligns with what we know about anxiety and depression treatment generally: adding structured psychological work consistently strengthens outcomes compared to pharmacotherapy alone.

Study details

Sources

Pharmacotherapy, acupoint stimulation, and psychotherapy for perimenopausal women with anxiety, depression, and panic disorder: a systematic review and network meta-analysis of randomized controlled trials. *Frontiers in Psychiatry*. PubMed: 42539596